Oncology

Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.

Black women are suggested to be diagnosed with stage 3 HR-positive breast cancer and receive longer neoadjuvant endocrine therapy more often than White women.

Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.

AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.

Study indicates that a diet high in ultra-processed food is more likely to increase the risk of colorectal cancer in men than it is women.

Analysis shows that individuals who are comfortable sharing their identities with providers are more likely to be satisfied with overall care.

Management of marginal zone lymphoma was impacted by the COVID-19 pandemic because some treatment options can reduce B-cell-produced antibodies.

NVG-111 is a humanized, tandem single-chain variable fragment ROR1 x CD3 BiTE being evaluated in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Eflapegrastism-xnst injection (Rolvedon, Spectrum Pharmaceuticals) is indicated to lower the incidence of infection, as demonstrated by febrile neutropenia, in adult patients with non-myeloid malignancies.

Researchers found differences in the variable importance of cancer mortality risk factors depending on an individual’s geographical region.

Prior authorizations have delayed time to treatment for patients and can directly impact clinical outcomes.

Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

New research presented at ESMO Congress found that certain patients with advanced melanoma administered a combination of cemiplimab with fianlimab experienced a median progression-free survival of 2 years.

Researchers at the European Society for Medical Oncology Congress presented findings that show osimertinib may clinically reduce the risk of lung cancer recurrence.

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.

Results demonstrated a 64.5% confirmed objective response rate in patients treated with the investigational combination.

Ribociclib with endocrine therapy was found to increase the median overall survival of patients with HR+/HER2- advanced breast cancer with visceral metastases to nearly 5 years.

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.

Data presented at the European Society for Medical Oncology Congress showed that sotorasib increased progression-free survival to 1 year in 25% of patients with KRAS G12C-mutated non-small cell lung cancer.

Fruquintinib reduced the risk of death in patients with advanced metastatic colorectal cancer by 34% and led to longer overall survival than among those given placebo.

Sunvozertinib is an oral, potent EGFR exon20ins inhibitor with wild-type EGFR selectivity.

But the 2021 modifications to the US Preventive Services Task Force recommendations do not eliminate the inequalities, analysis shows.

Study suggests that myeloma patient survival after BCMA-targeted T-cell therapy could be determined by microenvironment factors.

New TROPiCS-02 data for Gilead treatment demonstrates progression-free survival benefit, regardless of HER2 status.

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

Processed meats and products high in added sugars and low in fiber contribute to weight gain and obesity, which is an established risk factor.